Anticoagulation for cerebral venous sinus thrombosis

The Cochrane Library

Evidencia fiable. Decisiones informadas. Mejor salud.

Ir a:

Analysis 1.1

Comparison 1 Overall benefit or harm of (LMW) heparin, Outcome 1 Death.

Analysis 1.2

Comparison 1 Overall benefit or harm of (LMW) heparin, Outcome 2 Death or dependency.

Analysis 2.1

Comparison 2 Haemorrhagic adverse events, Outcome 1 Symptomatic intracerebral haemorrhage (new or increased).

Analysis 2.2

Comparison 2 Haemorrhagic adverse events, Outcome 2 Any severe haemorrhage.

Comparison 1. Overall benefit or harm of (LMW) heparin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Death Show forest plot	2	79	Risk Ratio (M‐H, Fixed, 95% CI)	0.33 [0.08, 1.28]

2 Death or dependency Show forest plot	2	79	Risk Ratio (M‐H, Fixed, 95% CI)	0.46 [0.16, 1.31]

Comparison 1. Overall benefit or harm of (LMW) heparin

Comparison 2. Haemorrhagic adverse events

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Symptomatic intracerebral haemorrhage (new or increased) Show forest plot	2	79	Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]

2 Any severe haemorrhage Show forest plot	2	79	Risk Ratio (M‐H, Fixed, 95% CI)	2.90 [0.12, 68.50]

Comparison 2. Haemorrhagic adverse events